The structure‐function relationship of human bleomycin hydrolase: mutation of a cysteine protease into a serine protease

Yi‐Zhen Zheng,Jingxuan Cui,Yung‐Lin Wang,Szu‐Jo Huang,En‐Chi Lin,Sheng‐Cih Huang,Jeffrey D. Rudolf,Xiaohui Yan,Chin‐Yuan Chang,Yi-Zhen Zheng,Yung-Lin Wang,Szu-Jo Huang,En-Chi Lin,Sheng-Cih Huang,Chin-Yuan Chang
DOI: https://doi.org/10.1002/cbic.202200186
IF: 3.2
2022-04-25
ChemBioChem
Abstract:Human bleomycin hydrolase (hBH) catalyzes deamidation of the anticancer drug, bleomycins (BLM). This enzyme is involved in BLM detoxification and drug resistance. Herein, we report the putative BLM‐binding site and catalytic mechanism of hBH. The crystal structures and biochemical studies support that hBH cleaves its C‐terminal residue without significant preference for the type of amino acids, and therefore can accordingly accommodate the β‐aminoalanine amide moiety of BLM for deamidation. Interestingly, hBH is capable of switching from a cysteine protease to a serine protease that is unable to cleave the secondary amide of hBH C‐terminus but reacts with the primary amide of BLMs.
biochemistry & molecular biology,chemistry, medicinal
What problem does this paper attempt to address?